Benitec Biopharma Inc.
NASDAQ:BNTCBiotechnology
+$0.36 today
- Market cap
- $288.53M
- Beta
- 0.28
- P/E (TTM)
- -12.3
- EPS (TTM)
- -$0.99
Volume 0.13M
Average 0.11M
BNTC Total Liabilities
Everything the company owes to creditors and other parties.
Benitec Biopharma Inc.NASDAQ: BNTC
Total Liabilities · Q3 FY2026 · quarter ended Mar 2026
Total liabilities falls 52.0% from a year ago
Total liabilities stood at $3.67M at the end of Q3 FY2026, down 52.0% from a year earlier and up 10.5% from the prior quarter. Over 3 fiscal years it compounded at -9.4% a year.
Context
- Total liabilities amounted to 2.0% of total assets at the end of Q3 FY2026, down 5.3 pp from a year earlier.
- Total liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total liabilities keeps falling in the next quarterly balance sheet after a -52.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 2.3M USD
- Year-over-year change
- -53.7%
- 4-year CAGR
- +13.8%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-06-30 | 2.3M | -53.7% |
| FY2024 | 2024-06-30 | 4.96M | +16.4% |
| FY2023 | 2023-06-30 | 4.26M | +37.9% |
| FY2022 | 2022-06-30 | 3.09M | +125.8% |
| FY2021 | 2021-06-30 | 1.37M | — |
Total Liabilities vs competitors
How BNTC compares with its peers on the latest reported figures
- BNTC's Mar 2026 total liabilities of $3.67M is the lowest of the 10 companies compared; the peer median is $56.84M.
- Its year-over-year change of -52.0% is the lowest of 10, against a peer median of +11.5%.
- Total liabilities amounts to 2.0% of total assets for BNTC, versus a peer median of 51.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $418.24M | +11.5% | +29.0% | 79.4% | |
| Dec 2025 | $229.03M | +17.6% | +13.9% | 42.8% | |
| Mar 2026 | $158.96M | +24.1% | +117.6% | 58.5% | |
| Mar 2026 | $146M | +19.9% | +39.7% | 926.4% | |
| Mar 2026 | $56.84M | +66.7% | +10.2% | 51.9% | |
| Mar 2026 | $51.1M | +5.3% | +17.1% | 89.8% | |
| Mar 2026 | $48.76M | -1.4% | +2.6% | 11.5% | |
| Mar 2026 | $25.36M | +7.9% | +30.6% | 9.6% | |
| Mar 2026 | $12.6M | -48.1% | -8.2% | 5.9% | |
| Mar 2026 | $3.67M | -52.0% | -9.4% | 2.0% | |
| Peer median (excluding BNTC) | $56.84M | +11.5% | +17.1% | 51.9% | |
Competitors are the stored peer set for BNTC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Benitec Biopharma Inc.
NASDAQ:BNTC
Intrinsic Alpha fair value
Locked
Current Price
$8.27
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.